Abstract
Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. Classic DLE lesions begin as red-purple macules, papules, or small plaques and rapidly develop a hyperkeratotic surface. Most patients with untreated classic DLE lesions suffer indolent progression to large areas of cutaneous dystrophy and scarring alopecia that can be psychosocially devastating. A 44-year-old male patient presented to the clinic with erythematous scaly patches that began on his nose 1 y before. His face was most affected, however, lesions were also noted on his scalp, ears, and limbs. Histopathologic examination verified a diagnosis of DLE. Laboratory examinations and consultations revealed no signs of systemic involvement. Imiquimod cream 5% was applied to the lesions once a day 3 times a week. After 20 applications, entire lesions regressed significantly. Imiquimod cream 5% may represent an alternative treatment method for patients with DLE.
Similar content being viewed by others
References
Gerdsen R, Wenzel J, Uerlich M, Bieber T, Petrow W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod.Dermatology. 2002; 205: 416–418.
Kuhn A, Becker-Wegerich PM, Ruzicka T, Lehmann P. Successful treatment of discoid lupus erythematosus with argon laser.Dermatology. 2000; 201: 175–177.
Molin L, Tarstedt M. Discoid lupus erythematosus treated with cryotherapy.J Dermatol Treat. 2003; 14: 182–183.
Alfadley A, Rayes HA, Hussein W, Dalan AA, Al-Aboud K. Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus.J Am Acad Dermatol. 2003; 48: 89–91.
Carrilo DR, Christensen OB. Treatment of chronic discoid lupus erythematosus with topical tacrolimus.Acta Derm Venereol. 2004; 84: 233–234.
Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod.J Am Acad Dermatol. 2000; 43: 6–11.
Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara).Expert Opin Investig Drugs. 1998; 7: 437–449.
Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.Leuk Lymphoma. 1995; 46: 935–939.
McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease.J Invest Dermatol. 2005; 125: 1–8.
Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review.J Cutan Med Surg. 2005 [Epub ahead of print].
Flórez A, Feal C, Torre C, Cruces M. Invasive squamous cell carcinoma treated with imiquimod 5% cream.Acta Derm Venereol. 2004; 84: 227–255.
Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream.Australas J Dermatol. 2003; 44: 281–283.
Mackenzie-Wood A, Kossard S, Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen’s disease.J Am Acad Dermatol. 2001; 44: 462–470.
Nicolas JF, Thivolet J, Kanitakis J, Lyonnet S. Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a.J Invest Dermatol. 1990; 95(6 suppl): 142–145.
Martinez J, de Misa RF, Boixeda P, Arrazola JM, Ledo A. Long-term results of intralesional interferon alpha-2B in discoid lupus erythematosus.J Dermatol. 1993; 20: 444–446.
Mori M, Pimpinelli N, Romagnoli P, Bernacchi E, Fabbri P, Giannotti B. Dendritic cells in cutaneous lupus erythematosus: a clue to the pathogenesis of lesions.Histopathology. 1994; 24: 311–321.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gül, Ü., Gönül, M., Çakmak, S.K. et al. A case of generalized discoid lupus erythematosus: Successful treatment with Imiquimod cream 5%. Adv Therapy 23, 787–792 (2006). https://doi.org/10.1007/BF02850319
Issue Date:
DOI: https://doi.org/10.1007/BF02850319